Abstract
Hypertrophic scar and keloid are common and difficult to treat diseases in plastic surgery. Results of wound healing research over the past decades have demonstrated that transforming growth factor-b (TGF-b) plays an essential role in cutaneous scar formation. In contrast, fetal wounds, which heal without scarring, contain a lower level of TGF-b than adult wounds. How to translate the discovery of basic scientific research into the clinical treatment of wound scarring has become an important issue to both clinicians and basic researchers. The development of gene therapy techniques offers the potential to genetically modify adult wound healing to a healing process similar to fetal wounds, and thus reduces wound scarring. This article intends to review the roles of TGF-b in the formation of wound scarring, the possible strategies of antagonizing wound TGF-b, and our preliminary results of scar gene therapy, which show that wound scarring can be significantly reduced by targeting wound TGF-b.
Keywords: wound scarring, gene therapy, adenovirus, gene transfer
Current Gene Therapy
Title: TGF-b: A Fibrotic Factor in Wound Scarring and a Potential Target for Anti- Scarring Gene Therapy
Volume: 4 Issue: 1
Author(s): W. Liu, D. R. Wang and Y. L. Cao
Affiliation:
Keywords: wound scarring, gene therapy, adenovirus, gene transfer
Abstract: Hypertrophic scar and keloid are common and difficult to treat diseases in plastic surgery. Results of wound healing research over the past decades have demonstrated that transforming growth factor-b (TGF-b) plays an essential role in cutaneous scar formation. In contrast, fetal wounds, which heal without scarring, contain a lower level of TGF-b than adult wounds. How to translate the discovery of basic scientific research into the clinical treatment of wound scarring has become an important issue to both clinicians and basic researchers. The development of gene therapy techniques offers the potential to genetically modify adult wound healing to a healing process similar to fetal wounds, and thus reduces wound scarring. This article intends to review the roles of TGF-b in the formation of wound scarring, the possible strategies of antagonizing wound TGF-b, and our preliminary results of scar gene therapy, which show that wound scarring can be significantly reduced by targeting wound TGF-b.
Export Options
About this article
Cite this article as:
Liu W., Wang R. D. and Cao L. Y., TGF-b: A Fibrotic Factor in Wound Scarring and a Potential Target for Anti- Scarring Gene Therapy, Current Gene Therapy 2004; 4 (1) . https://dx.doi.org/10.2174/1566523044578004
DOI https://dx.doi.org/10.2174/1566523044578004 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Seasonal and Perennial Allergic Conjunctivitis
Recent Patents on Inflammation & Allergy Drug Discovery The Response of the Aged Brain to Stroke: Too Much, Too Soon?
Current Neurovascular Research A Fatal Case of Acute Interstitial Pneumonia (AIP) in a Woman Affected by Glioblastoma
Current Drug Safety COX-2 in Brain and Spinal Cord - Implications for Therapeutic Use.
Current Medicinal Chemistry The Multifunctional Anti-inflammatory Drugs Used in the Therapy of Alzheimer’s Disease
Current Medicinal Chemistry Preclinical Models of Graves’ Disease and Associated Secondary Complications
Current Pharmaceutical Design Inflammatory Process as a Determinant Factor for the Degeneration of Substantia Nigra Dopaminergic Neurons: Possible Relevance to the Etiology of Parkinsons Disease
Current Medicinal Chemistry - Central Nervous System Agents Anti-inflammatory Potential of GSK-3 Inhibitors
Current Drug Targets Pharmacokinetic and Pharmacodynamic Properties of Anti-VEGF Drugs After Intravitreal Injection
Current Drug Metabolism Clinical Uses of Melatonin in Neurological Diseases and Mental and Behavioural Disorders
Current Medicinal Chemistry Unmasking Sex-Based Disparity in Neuronal Metabolism
Current Pharmaceutical Design Recent Progress in Anticonvulsant Drug Research: Strategies for Anticonvulsant Drug Development and Applications of Antiepileptic Drugs for Non-Epileptic Central Nervous System Disorders
Current Topics in Medicinal Chemistry Status Epilepticus in the Immature Rodent Brain Alters the Dynamics of Autophagy
Current Neurovascular Research General Anesthetics in Brain Injury: Friends or Foes?
Current Pharmaceutical Design Targeting Gender Difference in the Introduction of New Drugs for Diabetes Mellitus and Metabolic Disorders
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Mitochondria Sentencing About Cellular Life and Death: A Matter of Oxidative Stress
Current Pharmaceutical Design Pharmacokinetic Analysis of Tetramethylpyrazine Bis-Nitrone TN-2 in Rats and its Protein Binding In Vitro
Letters in Drug Design & Discovery Cyclooxygenase-2 Biology
Current Pharmaceutical Design Cytomegalovirus Infections in Non-Immunocompromised and Immunocompromised Patients in the Intensive Care Unit
Infectious Disorders - Drug Targets Novel Target Identification Technologies for the Personalised Therapy of Type II Diabetes and Obesity
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued)